Jinxin Reproduction (01951) announced interim results with profit attributable to shareholders of 107 million yuan, turning a year-on-year loss into profit

According to the Zhitong Finance App, Jinxin Production (01951) announced the results for the six months ended June 30, 2026, with revenue of RMB 1,373 billion (RMB, same below), up 6.57% year on year; profit attributable to shareholders was 107 million yuan, turning a year-on-year loss into a profit; basic profit per share was 0.04 yuan.

According to the announcement, the overall increase in revenue was mainly due to the following factors: (i) revenue from ARS and related services increased by about $17.2 million; (ii) revenue from management services increased by about $50.8 million; (iii) revenue from obstetrics and related medical services decreased by about $100,000; (iv) increased revenue from women's health services and other revenue by about $14.7 million; and (v) sales revenue related to medical consumables and equipment increased by about $2.1 million. The main reasons for the increase in revenue are: (a) Thanks to the official implementation of California's SB 729 Act in 2026 and successful doctors' reserves in the past three years, the number of egg retrieval cycles in the US reached a record high in the first half of the year, with revenue growth of 87.1 million yuan year-on-year; (b) the construction and business strategy of women's full life cycle and reproductive health management, which increased revenue from women's health services by 14.7 million yuan year on year.

According to reports, VIP products in the Chengdu Campus have entered the mature operation stage, and the service premium capacity is constantly increasing. In the first half of 2026, the VIP penetration rate in Chengdu Bisheng Campus reached 21.7%, an increase of about 1 percentage point over the previous year, and the customer unit price increased 6% to 71,000 yuan over the same period last year.

Since the complete operation of the Shenzhen hospital in the second quarter of 2026, with 40 years of medical technology accumulation and hardware upgrades in the new hospital, its high-net-worth business has begun to bear fruit in the first half of 2026. In addition to a sharp increase of 32.5% in initial infertility cases, the VIP penetration rate increased 6.9 percentage points to 9.2% year on year, and the initial diagnosis of Hong Kong patients increased 62% year on year. Relying on the location advantage of the Guangdong-Hong Kong-Macao Greater Bay Area in the future, it will focus on VIP and international business, and its high-net-worth business is expected to grow rapidly.